Highly Sensitive Assay for screening potential BACE1 inhibitors.

• Simple procedure takes one hour
• Fast and convenient
• The assay is sensitive, stable and high-throughput adaptable

β-Secretase (Beta-site amyloid precursor protein (APP) cleaving enzyme 1/BACE1), participates in the initial cleavage of amyloid precursor-APP generating two soluble N-terminal and C-terminal fragments. Another secretase isozyme, γ-Secretase, cleaves C-terminal fragment producing amyloid β.

Accumulation of amyloid β in brain results in the formation of amyloid plaques, which contribute in the development of Alzheimer’s disease (AD) in humans. Therefore, screening for novel and specific inhibitors of human β-Secretase (BACE1) has become critical in Alzheimer's disease-related drug discovery research.

Human β-Secretase (BACE1) inhibitor screening kit, human BACE1 cleaves a quenched substrate, specific for BACE1, generating a product with high fluorescence that can be measured at 435/500 nm. In the presence of BACE1 Inhibitor (control included in this kit), the enzymatic cleavage is impeded and could be used to screen for new inhibitor compounds.

All products are FOR RESEARCH USE ONLY.   PRODUCTS ARE NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES.  Customer is granted a limited use non-exclusive licence for its own internal research.  Any control manufacturer supplies with a Product is limited to use only to validate the relevant Product.  By using the Product, Customers agree not to attempt to reverse engineer or otherwise perform any compositional, structural, functional or other analyses directed to learning the methodology, formulae, sequences, processes, make-up or production of any of the Products or portions thereof.